Bendamustine-induced rash is associated with a favorable prognosis in patients with indolent B-cell lymphoma

Autor: Naoki Takahashi, Kunihiro Tsukasaki, Ken Tanae, Mika Kohri, Chie Asou, Daisuke Okamura, Maho Ishikawa, Tomoya Maeda, Nobutaka Kawai, Akira Matsuda, Tsugumi Sato, Hidekazu Kayano, Eiichi Arai, Norio Asou
Rok vydání: 2022
Předmět:
Zdroj: Journal of clinical and experimental hematopathology : JCEH. 62(1)
ISSN: 1880-9952
Popis: Bendamustine is now recognized as a key drug for indolent B-cell lymphoma (iBCL), mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Skin toxicity associated with bendamustine is one of the characteristic adverse effects. We retrospectively examined the relationship between bendamustine-associated drug rashes and disease prognosis of iBCL and MCL at our institution. Between January 2011 and August 2019, 65 patients (39 men and 26 women, median age 68, range 41-84 years) were treated with bendamustine alone (n=11, 120 mg/m
Databáze: OpenAIRE